A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects With Selected HER2 Positive Cancers
Phase of Trial: Phase I/II
Latest Information Update: 11 Feb 2017
Price : $35 *
At a glance
- Drugs SNX 5422 (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Esanex
- 20 Apr 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 20 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 21 Aug 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center: 13-112).